Australia markets closed

Oryzon Genomics S.A. (ORYZF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
4.00000.0000 (0.00%)
At close: 08:36AM EST
Full screen
Trade prices are not sourced from all markets
Previous close4.0000
Open4.1300
BidN/A x N/A
AskN/A x N/A
Day's range4.0000 - 4.0000
52-week range3.6000 - 4.7700
Volume200
Avg. volume3
Market cap211.046M
Beta (5Y monthly)1.05
PE ratio (TTM)N/A
EPS (TTM)-0.0820
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    ORYZON Announces New Global Chief Business Officer and Expansion of US Corporate Activities

    CBO joins from AIG Asset ManagementTo lead global business strategy and US corporate initiatives from US base MADRID, Spain and CAMBRIDGE, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that Dr. Saikat (“Sai”) Nandi has been appointed as Global Chief Business Officer (CBO). The appointment strengt

  • GlobeNewswire

    ORYZON Enrolls First Patient in EVOLUTION, a Phase IIb Clinical Trial With Vafidemstat in Schizophrenia

    Primary objectives: to assess the effect of vafidemstat to address negative and cognitive symptoms in schizophreniaPhase IIb adaptive trial planning to enroll 100 patientsSecond Phase IIb study of vafidemstat in CNS disorders MADRID, Spain and CAMBRIDGE, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today the

  • GlobeNewswire

    ORYZON Publishes Paper in ACS Pharmacology & Translational Science Supporting Best-in-Class Performance of Iadademstat in Oncology

    Iadademstat consistently stronger in viability reduction in AML & SCLC cellsSuperior target engagement at low concentration in AML & SCLC cells Superior disruption of the Snag-domain protein-protein interactions MADRID, Spain and CAMBRIDGE, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announces the publication of a sc